Ligand Pharmaceuticals stock is on the rise with optimistic analyst ratings and a plan for 20% annual revenue growth. Learn ...

New drug approvals and strong pipeline progress are likely to help ... it through our "Recent Price Strength" screen. Data support Ohtuvayre™ (ensifentrine), as a first-in-class, selective ...

TOKYO, Jan 31 (Reuters) - Japan is considering offering support for a $44 billion gas pipeline in Alaska as it seeks to court U.S. President Donald Trump and forestall potential trade friction ...

The company bagged FDA approval for first-in-class dual phosphodiesterase (PDE) 3/4 inhibitor Ohtuvayre (ensifentrine) last June, becoming the first inhaled product with a novel mechanism of ...

Elizabeth Corner speaks to Kevin O’Donnell, Executive Director of the PLCAC, about how membership organisations benefit the pipeline sector and those who work in it, discussing events, networking, ...

The first-in-class dual phosphodiesterase (PDE) 3/4 inhibitor – now given the somewhat tongue-twisting brand name of Ohtuvayre – is the first inhaled product with a novel mechanism of action ...

Zacks Small Cap Research was hard at work in 2024 initiating analyst coverage on 40 companies. Each of our initiation reports provides a valuation, investment thesis and financial forecast model ...

Sanofi S.A. Part Cert-1.97% €8.03M ...

Barbara Obstoj-Cardwell is the Managing Editor of The Pharma Letter, which in 2010 acquired the archives of The Pharma Marketletter, a publication that Barbara owned since 1991 and prior to that ...

After hours: 31 January at 7:50:01 pm GMT-5 ...